These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 112438)

  • 1. [Venous effect of Daflon. Clinical and pharmacological study using xenon-133-clearance].
    Klemm J
    MMW Munch Med Wochenschr; 1979 Jun; 121(26):891-2. PubMed ID: 112438
    [No Abstract]   [Full Text] [Related]  

  • 2. Activity of Daflon 500 mg on the hemorheological disorders in diabetes.
    Lacombe C; Lelievre JC; Bucherer C; Grimaldi A
    Int Angiol; 1989; 8(4 Suppl):45-8. PubMed ID: 2632648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthetic Diosmin in the therapy of venous diseases.
    Signorelli S; Ferrara M; Tornetta D; Interlandi S; Amico-Roxas MT; Monaco S; Andreozzi GM
    Panminerva Med; 1987; 29(2):165-7. PubMed ID: 3627817
    [No Abstract]   [Full Text] [Related]  

  • 4. Effects of Daflon 500 mg on bovine vessels contractility.
    Gargouil YM; Perdrix L; Chapelain B; Gaborieau R
    Int Angiol; 1989; 8(4 Suppl):19-22. PubMed ID: 2632645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Venous elasticity after treatment with Daflon 500 mg.
    Ibegbuna V; Nicolaides AN; Sowade O; Leon M; Geroulakos G
    Angiology; 1997 Jan; 48(1):45-9. PubMed ID: 8995343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Evaluation of the venotropic effect of chromocarb diethylamine in patients with varices, using 133Xe].
    Spano V; Mancini A; Slatopolsky-Cantis M
    Ann Cardiol Angeiol (Paris); 1984 Oct; 33(6):407-10. PubMed ID: 6497304
    [No Abstract]   [Full Text] [Related]  

  • 7. Mechanisms in experimental venous valve failure and their modification by Daflon 500 mg.
    Pascarella L; Lulic D; Penn AH; Alsaigh T; Lee J; Shin H; Kapur V; Bergan JJ; Schmid-Schönbein GW
    Eur J Vasc Endovasc Surg; 2008 Jan; 35(1):102-10. PubMed ID: 17890112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lymphagogue and pulsatile activities of Daflon 500 mg on canine thoracic lymph duct.
    Cotonat A; Cotonat J
    Int Angiol; 1989; 8(4 Suppl):15-8. PubMed ID: 2632644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Are the phlebotonic properties shown in clinical pharmacology predictive of a therapeutic benefit in chronic venous insufficiency? Our experience with Daflon 500 mg.
    Tsouderos Y
    Int Angiol; 1989; 8(4 Suppl):53-9. PubMed ID: 2698902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hemorheological improvement after Daflon 500 mg treatment in diabetes.
    Lacombe C; Bucherer C; Lelievre JC
    Int Angiol; 1988; 7(2 Suppl):21-4. PubMed ID: 3183453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Diosmin in the treatment of venous disease: pharmacokinetics and pharmacodynamics (in Russian only)].
    Talibov OB
    Khirurgiia (Mosk); 2019; (3):135-140. PubMed ID: 30938369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vital capillaroscopy on microcirculation: pharmacodynamic activity of Daflon 500 mg in venous insufficiency.
    Balas P; Pagratis N
    Int Angiol; 1989; 8(4 Suppl):51-2. PubMed ID: 2632650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Modification of lysosomal enzymes using semisynthetic diosmin. Comparative clinical study].
    Marescaux J; Maamer M; Trenque T; Evrard S; Mutter D; Furderer C
    Phlebologie; 1987; 40(4):1043-55. PubMed ID: 3447185
    [No Abstract]   [Full Text] [Related]  

  • 14. [Study of the pharmacodynamic activity of daflon 500 mg].
    Amiel M; Barbe R
    Ann Cardiol Angeiol (Paris); 1998 Mar; 47(3):185-8. PubMed ID: 9772947
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacologic properties of Daflon 500 mg.
    Labrid C
    Angiology; 1994 Jun; 45(6 Pt 2):524-30. PubMed ID: 8203782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advantage of a micronized flavonoidic fraction (Daflon 500 mg) in comparison with a nonmicronized diosmin.
    Amato C
    Angiology; 1994 Jun; 45(6 Pt 2):531-6. PubMed ID: 8203783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mediators involved in inflammation: effects of Daflon 500 mg on their release.
    Jean T; Bodinier MC
    Angiology; 1994 Jun; 45(6 Pt 2):554-9. PubMed ID: 8203787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lymphatic system and microcirculation. Proceedings of the Third International Symposium on Daflon 500 held during the First Mediterranean Congress of Angiology. Corfu, Greece, May 31, 1988.
    Int Angiol; 1989; 8(4 Suppl):1-75. PubMed ID: 2632643
    [No Abstract]   [Full Text] [Related]  

  • 19. The human saphenous vein in pharmacology: effect of a new micronized flavonoidic fraction (Daflon 500 mg) on norepinephrine induced contraction.
    Juteau N; Bakri F; Pomies JP; Foulon C; Rigaudy P; Pillion G; Lange G; Genre O; Cron JP
    Int Angiol; 1995 Sep; 14(3 Suppl 1):8-13. PubMed ID: 8919257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of Daflon 500 mg* on haemoconcentration and alterations of white blood cell count elicited by the upright position in anaesthetized dogs.
    Delbarre B; Delbarre G; Pillion G; Calinon F
    Int Angiol; 1995 Sep; 14(3 Suppl 1):23-5. PubMed ID: 8919260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.